Top news of the week: 30.08.2022.
For the ‘godfather’ of biotech, saving Biogen is the final act of a singular career
In the history of the global pharmaceutical industry, there have been many big thinkers, brash visionaries, and billionaire disruptors. But there has only ever been one Godfather.
Gene therapies must become miracles of medicine
Otherwise they might end up a niche treatment for a small number of patients in rich countries
Vilya Launches to Design a New Transformational Class of Medicines That Precisely Target Disease Biology
VILYA, Inc. (Vilya), a biotechnology company creating a new class of medicines that precisely target disease biology, announced its launch today. Vily
Roots Rapper Blazes A Trail Forward, From ‘The Tonight Show’ To Venture Capital
As the rapper for Grammy-winning band The Roots, Tariq Trotter, aka Black Thought, has performed in front of millions on The Tonight Show Starring Jimmy Fallon. Still, he said he felt ...
Backed by $40M, a biotech startup targets cancer with help from the immune system
After several years in stealth, 3T Biosciences is launching publicly with plans to develop newer types of T cell receptor-based treatments.
Atlas Venture’s Bruce Booth on testing the IPO waters and putting the ‘tech’ in biotech
In a wide-ranging conversation with BioPharma Dive, Booth, a prolific builder of new biotechs, said he’s starting to see positive signs for startups considering an IPO or private financing.
See the 27-slide presentation a secretive biotech startup backed by Sean Parker used to raise $40 million and 'open a new universe' in cancer immunotherapy
3T Biosciences started in 2017 and is backed by Sean Parker and Peter Thiel. The former R&D head of biotech giant Amgen is guiding its next chapter.
Ovid turns to gene therapy startup to restock drug pipeline
The New York biotech will invest in and develop up to three drugs with Gensaic, an emerging startup aiming to use the viruses that infect bacteria to deliver genetic medicines.